Drug Trial Radar · NCT04120246
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
24
Planned (sponsor's estimate)
Start
Apr 8, 2020
Primary completion
Feb 1, 2028
Study completion Feb 1, 2030
Sponsor
- Lead sponsor
- Veana TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- University of Washington
- First posted
- Oct 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the side effects and best dose of alpha-TEA when given together with trastuzumab and to see how well they work for the treatment of HER2+ breast cancer that does not respond to treatment (refractory) and has spread to other places in the body (metastatic). Anti-cancer treatment, such as alpha-TEA, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Alpha-TEA may also alter cancer growth by stimulating the body's immune response against the tumor. Trastuzumab is a form of "targeted therapy" because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Giving alpha-TEA and trastuzumab may work better for the treatment of HER2+ refractory and metastatic breast cancer compared to usual treatment.
Conditions
- Anatomic Stage IV Breast Cancer AJCC v8
- HER2 Positive Breast Carcinoma
- Metastatic Breast Carcinoma
- Refractory Breast Carcinoma
Interventions
Alpha-tocopheryloxyacetic AcidDrug
Given PO
TrastuzumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events of 4 escalating doses of alpha-tocopheryloxyacetic acid (TEA) therapy when combined with trastuzumabTime frame: Up to 4 years
- Clinical response rate of alpha-TEA when combined with trastuzumabTime frame: Up to 4 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Providence Cancer Institute - Franz Clinic
Portland, Oregon
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.